CN113329750B - 用于治疗沙粒病毒感染的化合物 - Google Patents

用于治疗沙粒病毒感染的化合物

Info

Publication number
CN113329750B
CN113329750B CN201980080594.2A CN201980080594A CN113329750B CN 113329750 B CN113329750 B CN 113329750B CN 201980080594 A CN201980080594 A CN 201980080594A CN 113329750 B CN113329750 B CN 113329750B
Authority
CN
China
Prior art keywords
compound
group
compounds
pharmaceutically acceptable
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980080594.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113329750A (zh
Inventor
E.布朗
V.R.甘特拉
N.索科洛娃
M.B.普勒韦
G.亨克尔
K.麦克科马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alison Therapeutic Drugs
Original Assignee
Alison Therapeutic Drugs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alison Therapeutic Drugs filed Critical Alison Therapeutic Drugs
Publication of CN113329750A publication Critical patent/CN113329750A/zh
Application granted granted Critical
Publication of CN113329750B publication Critical patent/CN113329750B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980080594.2A 2018-12-06 2019-12-03 用于治疗沙粒病毒感染的化合物 Active CN113329750B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776390P 2018-12-06 2018-12-06
US62/776,390 2018-12-06
PCT/US2019/064223 WO2020117794A1 (en) 2018-12-06 2019-12-03 Compounds for the treatment of arenavirus infection

Publications (2)

Publication Number Publication Date
CN113329750A CN113329750A (zh) 2021-08-31
CN113329750B true CN113329750B (zh) 2025-10-17

Family

ID=70975517

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980080594.2A Active CN113329750B (zh) 2018-12-06 2019-12-03 用于治疗沙粒病毒感染的化合物

Country Status (10)

Country Link
EP (1) EP3890731A4 (https=)
JP (1) JP7675009B2 (https=)
KR (1) KR20210106997A (https=)
CN (1) CN113329750B (https=)
AR (1) AR117228A1 (https=)
AU (1) AU2019393784B2 (https=)
BR (1) BR112021010909A2 (https=)
EA (1) EA202191001A1 (https=)
MX (2) MX2021005234A (https=)
WO (1) WO2020117794A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116217490B (zh) * 2023-02-03 2025-09-26 中国人民解放军军事科学院军事医学研究院 一种苯并咪唑类化合物及其制备方法和应用
EP4434972A1 (en) * 2023-03-22 2024-09-25 Eberhard-Karls-Universität Tübingen Atm kinase inhibitors
WO2025137345A1 (en) * 2023-12-20 2025-06-26 Arisan Therapeutics Inc. Crystalline forms of an imidazopyridine derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013430A2 (en) * 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
AP3675A (en) * 2012-02-17 2016-04-15 Kineta Four Llc Antiviral drugs for treatment of arenavirus infection
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018013430A2 (en) * 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Discovery of a novel highly potent broad-spectrum heterocyclic chemical series of arenavirus cell entry inhibitors;Plewe MB，等;Bioorg Med Chem Lett;20210505;第41卷;第127983页 *

Also Published As

Publication number Publication date
EP3890731A4 (en) 2022-08-17
MX2021005234A (es) 2021-08-11
AU2019393784B2 (en) 2025-06-12
JP2022509763A (ja) 2022-01-24
MX2024013042A (es) 2024-12-06
CA3118765A1 (en) 2020-06-11
EA202191001A1 (ru) 2021-08-16
AU2019393784A1 (en) 2021-05-27
EP3890731A1 (en) 2021-10-13
JP7675009B2 (ja) 2025-05-12
WO2020117794A1 (en) 2020-06-11
CN113329750A (zh) 2021-08-31
BR112021010909A2 (pt) 2021-08-24
KR20210106997A (ko) 2021-08-31
AR117228A1 (es) 2021-07-21

Similar Documents

Publication Publication Date Title
US11352328B2 (en) Heterocyclic compounds for the treatment of arenavirus
AU2018331172B2 (en) Influenza virus replication inhibitor and use thereof
CN101098872B (zh) 可用作蛋白激酶抑制剂的吡咯并吡嗪和吡唑并吡嗪
WO2022013684A1 (en) Antiviral heteroaryl ketone derivatives
CN113329750B (zh) 用于治疗沙粒病毒感染的化合物
TW202330538A (zh) 螺環化合物
EP3033341B1 (en) Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
TW201138786A (en) Therapeutic compounds
CN119546574A (zh) 抗病毒吲哚啉基化合物和其用途
CN106879256A (zh) 2‑氨基‑苯并咪唑衍生物及其作为5‑脂氧合酶和/或前列腺素e合成酶抑制剂的应用
JP2022548907A (ja) ベンズイミダゾールおよびそれを使用する方法
CN101087785A (zh) 作为丙型肝炎病毒抑制剂的4－甲氧基甲基－吡咯烷－2－羧酸化合物及其衍生物
EP3204375A1 (en) Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (rsv)
CN117088869A (zh) 一种3cl蛋白酶抑制剂及其制备方法和应用
CN112062800B (zh) 核苷化合物的氨基磷酸酯衍生物及其用途
MX2014015648A (es) Cianoguanidinas y usos de las mismas.
WO2007039145A1 (en) C (2) -heteroarylmethyl-c (4) -pyrazinyl-2-yl acyl pyrrolidine compounds and their use for treating viral infections, especially hepatitis c virus
JP2025503995A (ja) 化合物及びその医学的使用
US12419865B2 (en) Compounds for the treatment of arenavirus infection
CN114466848A (zh) 抗细菌化合物
CA3118765C (en) Compounds for the treatment of arenavirus infection
EA044865B1 (ru) Соединения для лечения аренавирусной инфекции
EP4125872A1 (en) Substituted azole dione compounds with antiviral activity
OA20266A (https=)
WO2021262426A9 (en) Adamantane amides and thioamides for the treatment of ebolavirus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20400215